Home
 /
Papers
 /
Bioinformatics
 /
Pan-cancer virtual spatial transcriptomics from routine histology with Phoenix
Preprint
Open access
Top 1% · Validated by QED

Pan-cancer virtual spatial transcriptomics from routine histology with Phoenix

Manuel Tran, Rushin H. Gindra, Philipp Putze +21 more
April 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.04.25.720812
99
%
QED Score
QED Impressions

By inferring spatially resolved gene expression zero-shot from routine histology across cancers, cohorts, and species, Phoenix replaces prohibitively expensive assays with scalable computation—making population-level spatial biology achievable from any pathology archive.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Phoenix, a latent flow matching generative model, accurately predicts spatially resolved single-cell gene expression from routine histology with zero-shot generalization across unseen cohorts, tissues, and species, enabling population-scale spatial transcriptomics that reveals three conserved tumor ecosystems across 9,544 human cancers with distinct clinical outcomes and identifies transferable spatial biomarkers that predict treatment response across multiple cancer types and therapeutic regimens.

See full analysis
Main Claim 1 –

Phoenix predicts single-cell spatial expression from histology, zero-shot generalization

Supporting evidence

  • Phoenix preserves spatial expression architecture while baselines collapse to mean
  • Phoenix recovers known cancer biology and generates testable hypotheses
  • Phoenix predicts sarcoma cell-type signatures and chemotherapy immune remodeling
  • Phoenix predicts mouse PDAC lineage markers and mKrasG12D expression
Main Claim 2 –

Population-scale Phoenix reveals three conserved tumor ecotypes with prognostic impact

Main Claim 3 –

Phoenix-derived spatial biomarkers predict therapy response across cancers and regimens

Abstract

Spatial transcriptomics links gene expression to tissue architecture, providing a mechanistic view of cellular organization. Yet existing datasets cover few donors and miss the complexity of human disease. Experimental costs remain prohibitive, and large-scale profiling is impractically slow for population-level studies. Accurate computational methods are urgently needed. Predicting gene expression from standard histology, however, remains an open problem, as current approaches transfer poorly to unseen cohorts and diseases. Here, we present Phoenix, a latent flow matching generative model that infers pan-cancer spatially resolved single-cell gene expression with high accuracy. Phoenix analyzes treatment response in silico: Applied to 763 head and neck cancer patients, it identified three new spatial biomarkers that we validated across two cancers (breast cancer, n = 84; ovarian cancer, n = 157) and treatment regimens (platinum, trastuzumab). Phoenix generalizes beyond carcinomas: In a large sarcoma cohort (802 tissue microarray cores), it accurately predicted cell-type-specific signatures in held-out samples and captured chemotherapy-induced immune remodeling. Phoenix also extends across species: In a mouse model, it accurately predicted the expression of pancreatic cancer lineage markers and the mutant mKras^G12D allele in silico. Together, Phoenix establishes virtual spatial transcriptomics from routine histology as a scalable framework for studying tissue organization, therapeutic response, and disease mechanisms.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?